SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

08 Nov 2025 Evaluate
The sales for the September 2025 quarter moved up 37.03% to Rs. 5590.90 millions as compared to Rs. 4080.00 millions during the corresponding quarter last year.Net Profit recorded in the quarter ended September 2025 rise to 41.09% to Rs. 542.20  millions  compared to R. 384.30 millions in corresponding previous quarter.The company reported a good operating profit of 813.50 millions compared to 606.90 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 5590.90 4080.00 37.03 10854.00 7955.20 36.44 17162.90 12955.30 32.48
Other Income 61.70 81.50 -24.29 174.10 165.00 5.52 406.30 348.00 16.75
PBIDT 813.50 606.90 34.04 1737.00 1071.10 62.17 2946.00 2192.50 34.37
Interest 6.70 3.40 97.06 13.90 4.50 208.89 14.60 12.00 21.67
PBDT 753.90 603.50 24.92 1666.60 491.00 239.43 1963.50 2344.80 -16.26
Depreciation 25.70 93.20 -72.42 191.40 132.30 44.67 399.90 149.40 167.67
PBT 728.20 510.30 42.70 1475.20 358.70 311.26 1563.60 2195.40 -28.78
TAX 186.00 126.00 47.62 374.70 92.30 305.96 406.20 580.30 -30.00
Deferred Tax -4.10 -21.00 -80.48 -36.40 -162.20 -77.56 -199.20 -9.00 2113.33
PAT 542.20 384.30 41.09 1100.50 266.40 313.10 1157.40 1615.10 -28.34
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 14.55 14.88 -2.18 16.00 13.46 18.86 17.16 16.92 1.43

Astrazeneca Pharma I Share Price

8567.20 -150.85 (-1.73%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×